Oss, September, 13th, 2016 – NTRC will join a mission of European biotechnology companies to Japan, which has been organized by the EU-Japan Centre for Industrial Cooperation. Twenty representatives from eight different European countries, mainly from research-driven small and medium enterprises (SME) will participate in this mission. During the mission two conferences will be attended at which one-to-one business partnering meetings can be scheduled with NTRC.
On Tuesday, October 11th, NTRC will participate in the European Biotech and Pharma Partnering Conference at the Senri-Life Science Centre in Osaka.
Website: https://www.b2match.eu/euj-bio-pharma-be-2016
From Wednesday, October 12th to Friday, October 14th, NTRC will attend BIO Japan 2016, organized at the Pacifico convention complex in Yokohama.
On Thursday October 13th, 1.30 p.m., Dr. Guido Zaman will present NTRC’s drug discovery programs and services during a symposium enabled by the EU-Japan Centre (Location: Seminar Stage C). NTRC’s services will also be presented on a poster in Booth C-31 in the Exhibition area.
Invitations for one-to-one business meetings with NTRC can be send through the website of the conferences.
About NTRC
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, SynergyFinder™ and OncolinesProfiler™), target residence time measurements for protein kinases (ResidenceTimer™), and developing new enabling technologies, such as NFK GreenScreen™. In addition, NTRC develops own novel targeted therapies based on small molecules, such as selective inhibitors of TTK (Mps1) protein kinase for chromosomal unstable tumours and inhibitors of the tryptophan metabolizing enzymes IDO1 and TDO for cancer immunotherapy. For more information please visit www.ntrc.nl or contact info@ntrc.nl
